There are currently 917 clinical trials in Washington, District Of Columbia looking for participants to engage in research studies. Trials are conducted at various facilities, including Children's National Medical Center, MedStar Georgetown University Hospital, MedStar Washington Hospital Center and Walter Reed Army Medical Center. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Aventus Thrombectomy System Pulmonary Embolism Clinical Study
Recruiting
Evaluate the safety and efficacy of the Aventus Thrombectomy System for aspiration thrombectomy in subjects with acute pulmonary embolism.
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
04/03/2024
Locations: Medstar, Washington, District of Columbia
Conditions: Pulmonary Embolism, Embolism, Embolism and Thrombosis, Vascular Diseases, Cardiovascular Diseases, Lung Diseases, Respiratory Tract Diseases
Assessment of Safety and Effectiveness of NovoSorb® BTM in Severe Burns
Recruiting
This is a multi-center, pivotal study to assess the safety and effectiveness of a new method of treating severe burns using NovoSorb® Biodegradable Temporizing Matrix (BTM).
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
04/03/2024
Locations: MedStar Washington Hospital Center, Washington, District of Columbia
Conditions: Burns
Study to Evaluate the Safety, Phage Kinetics, and Efficacy of Inhaled AP-PA02 in Subjects With Non-Cystic Fibrosis Bronchiectasis and Chronic Pulmonary Pseudomonas Aeruginosa Infection
Recruiting
A phase 2, multi-center, double-blind, randomized, placebo-controlled study to evaluate the safety, phage kinetics, and efficacy of inhaled AP-PA02 administered in subjects with non-cystic fibrosis bronchiectasis and chronic pulmonary Pseudomonas aeruginosa infection.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/02/2024
Locations: Georgetown University Hospital / Pulmonary Critical Care and Sleep Medicine, Washington, District of Columbia
Conditions: Non-cystic Fibrosis Bronchiectasis, Pseudomonas Aeruginosa, Lung Infection
Durvalumab and Tremelimumab in Combination With Chemotherapy in Virus-infected Patients With Non-small Cell Lung Cancer
Recruiting
This is a phase II trial of durvalumab and tremelimumab in combination of platinum-based chemotherapy. Patients with stage IV Non-Small-Cell-Lung Cancer (NSCLC) with human immunodeficiency virus (HIV) infection (cohort 1) or hepatitis B virus (HBV), or hepatitis C virus (HCV) infection (cohort 2) will be eligible. Patients will receive standard platinum-based chemotherapy plus durvalumab for 4 cycles (every 3 weeks), followed by durvalumab (with or without pemetrexed for non-squamous NSCLC) main... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/02/2024
Locations: Georgetown Lombardi Comprehensive Cancer Center, Washington, District of Columbia +1 locations
Conditions: Carcinoma, Non-Small Cell Lung
Hospital-Based Cluster Trial: Magnetically Controlled Growing Rods Using Distraction Intervals
Recruiting
A hospital-based cluster stratified randomization control study will be conducted to investigate spinal growth in Early Onset Scoliosis patients between 5 and 9 years of age. Patients must have a major coronal curve measuring over 50 degrees and be undergoing Magnetically Controlled Growing Rod treatment. We will be studying 6-week lengthening intervals compared to 16-week lengthening intervals on spinal growth within 3 years.
Gender:
All
Ages:
Between 5 years and 9 years
Trial Updated:
04/01/2024
Locations: Children's National Health System, Washington, District of Columbia
Conditions: Early-Onset Scoliosis Deformity of Spine
Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory Classical Hodgkin Lymphoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
Recruiting
This phase I trial studies the side effects and best dose of nivolumab when given with ipilimumab in treating patients with human immunodeficiency virus (HIV) associated classical Hodgkin lymphoma that has returned after a period of improvement (relapsed) or does not respond to treatment (refractory), or solid tumors that have spread from where it first started to other places in the body (metastatic) or cannot be removed by surgery (unresectable). Immunotherapy with monoclonal antibodies, such... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
03/29/2024
Locations: George Washington University Medical Center, Washington, District of Columbia
Conditions: Advanced Malignant Solid Neoplasm, Anal Carcinoma, HIV Infection, Kaposi Sarcoma, Lung Carcinoma, Metastatic Malignant Solid Neoplasm, Recurrent Classic Hodgkin Lymphoma, Refractory Classic Hodgkin Lymphoma, Unresectable Solid Neoplasm
Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors
Recruiting
IMC-F106C is an immune-mobilizing monoclonal T cell receptor against cancer (ImmTAC ®) designed for the treatment of cancers positive for the tumor-associated antigen PRAME. This is a first-in-human trial designed to evaluate the safety and efficacy of IMC-F106C in adult patients who have the appropriate HLA-A2 tissue marker and whose cancer is positive for PRAME.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/28/2024
Locations: Georgetown University Medical Center, Washington, District of Columbia
Conditions: Select Advanced Solid Tumors
JAGUAR Trial: ObJective Analysis to GaUge EVAR Outcomes Through Randomization
Recruiting
Prospective, randomized, multi-center study designed to evaluate the outcomes of commercially available contemporary EVAR in a real-world population. Patients will be randomized into two device cohorts and compared across the primary endpoints. Patients will be followed procedurally to discharge, at 1, 6, 12 months and annually through to 5 years (total follow-up commitment).
Gender:
All
Ages:
21 years and above
Trial Updated:
03/28/2024
Locations: MedStar Washington Hospital Center, Washington, District of Columbia
Conditions: AAA, AAA - Abdominal Aortic Aneurysm
Clinical Evaluation of the AccuCinch® Ventricular Restoration System in Patients Who Present With Symptomatic Heart Failure With Reduced Ejection Fraction (HFrEF): The CORCINCH-HF Study
Recruiting
Prospective, randomized, open-label, international, multi-center clinical study to evaluate the safety and efficacy of the AccuCinch Ventricular Restoration System in patients with heart failure and reduced ejection fraction (HFrEF).
Gender:
All
Ages:
18 years and above
Trial Updated:
03/27/2024
Locations: Medstar Health Research Institute, Washington, District of Columbia
Conditions: Heart Failure With Reduced Ejection Fraction (HFrEF), Dilated Cardiomyopathy
BOLT: Study of the Indigo® Aspiration System When Used in Patients With Deep Vein Thrombosis
Recruiting
The objective of this study is to demonstrate the safety and efficacy of the Indigo Aspiration system for percutaneous mechanical thrombectomy in a population presenting with obstruction due to deep vein thrombosis (DVT) who are eligible for treatment.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/27/2024
Locations: MedStar Washington, Washington, District of Columbia
Conditions: Deep Vein Thrombosis, DVT
Cold Agglutinin Disease Real World Evidence Registry
Recruiting
This is a multinational, multi-center, observational, prospective, longitudinal disease registry designed to collect data on participants with cold agglutinin disease (CAD) or cold agglutinin syndrome (CAS). Among them, a minimum of 30 patients with CAD treated with sutimlimab are expected to take part in the sutimlimab cohort study. Patients with CAD who have been enrolled in previous sutimlimab clinical trials (e.g., BIVV009-01/LTS16214 [NCT02502903,CAD patients], BIVV009-03/EFC16215 [NCT03347... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
03/27/2024
Locations: MedStar Georgetown University Hospital / Lombardi Comprehensive Cancer Center Site Number : 1208, Washington, District of Columbia
Conditions: Cold Agglutinin Disease (CAD), Cold Agglutinin Syndrome (CAS)
Pediatric Percutaneous Ultrasound Gastrostomy Technique
Recruiting
The purpose of this research study is to test a new device called the PUMA-G Pediatric System. The research will measure if the device works well to safely aid doctors placing gastrostomy feeding tubes in children. The PUMA-G Pediatric System is an investigational device that uses ultrasound and magnets to guide insertion of a feeding tube.
Gender:
All
Ages:
Between 0 years and 21 years
Trial Updated:
03/27/2024
Locations: Children's National Hospital, Washington, District of Columbia
Conditions: Gastrostomy, Gastrostomy Complications, Pediatric Disorder, Ultrasound